NCT04567290

Pharmacodynamic Evaluation of Antiplatelet Effect of Swallowing Versus Chewing Ticagrelor in Patients With Acute Coronary Syndrome

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: Centro Hospitalario La Concepcion · Academic / Other
• Sex: All
• Age: 19 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

The study aims to determine the pharmacodynamic performance in the first hour measured with verifynow, of the conventional ticagrelor loaded dose versus chewed ticagrelor in patients with acute coronary syndrome treated with percutaneous coronary intervention

Conditions

• Acute Coronary Syndrome

Interventions

Type	Name	Description
DRUG	Chewed ticagrelor	Chewed ticagrelor (Brilinta) 90 mg tablets, 2 tablets
DRUG	Swallowed ticagrelor	Swallowed ticagrelor (Brilinta) 90 mg tablets, 2 tablets

Timeline

• Start date: 2020-10-07
• Primary completion: 2021-08-15
• Completion: 2021-09-30
• First posted: 2020-09-28
• Last updated: 2021-07-29

Locations

1 site across 1 country: Mexico